Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288613 · ClinicalTrials.gov registry record
FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study
A clinical trial of Kidney Failure, Chronic and End Stage Renal Disease, Requiring Dialysis, sponsored by NxStage Medical.
- Completed
- Registry status
- 501
- Enrollment target
- 20
- Study locations
NCT00288613 is a study of Kidney Failure, Chronic and End Stage Renal Disease, Requiring Dialysis that has completed, run by NxStage Medical. The registered enrollment target is 501 participants, above the 310-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT00288613, a study of Kidney Failure, Chronic and End Stage Renal Disease, Requiring Dialysis, has completed, sponsored by NxStage Medical.
- COMPLETED
- Registry status
- 501 participants
- Enrollment target
- 20
- Study locations
Study Summary
Purpose The purpose of this study is to compare the economical impact and clinical parameters of short daily hemodialysis using the NxStage® System One hemodialysis device with thrice-weekly conventional in-center dialysis using a matched cohort from the US Renal Data System (USRDS) database.
Conditions Studied
Study Locations (20)
California
- Renal Advantage (RAI) - Garden Grove
- Satellite Healthcare/Wellbound - Mountain View
- Renal Advantage (RAI) - Oakland
- Kidney Center, Inc. - Simi Valley
Michigan
- Great Lakes Renal Network - Alma
- Henry Ford Health System - Detroit
- Munson Dialysis Center - Traverse City
Arkansas
- Fort Smith Regional Dialysis Center - Fort Smith
- Arkansas Nephrology Research Associates - Hot Springs
Illinois
- Circle Medical Management - Chicago
- Affiliated Home Dialysis - Glen Ellyn
Indiana
- Indiana University Medical Center - Indianapolis
- Nephrology, Inc. - Mishawaka
Colorado
- University of Colorado Hospital - Aurora
Connecticut
- Metabolism Associates - New Haven CAPD - New Haven
Florida
- RAI Palm Harbor, Outcomes Research Int'l - Hudson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2006-01 |
| Est. Completion | 2013-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288613
The ClinicalTrials.gov registry entry for NCT00288613 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 310-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (62% higher). The listed sponsor is NxStage Medical, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 0 interventions.
NCT00288613 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Michigan, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00288613 about?
NCT00288613 is a clinical study titled "FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study". Purpose The purpose of this study is to compare the economical impact and clinical parameters of short daily hemodialysis using the NxStage® System One hemodialysis device with thrice-weekly conventional in-center dialysis using a matched cohort from the US Renal Data System (USRDS) database.
What is the current status of trial NCT00288613?
This trial is currently completed. The enrollment target is 501 participants. The study started on 2006-01. Estimated completion is 2013-11.
What conditions does trial NCT00288613 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic, End Stage Renal Disease, Requiring Dialysis.
Who is sponsoring clinical trial NCT00288613?
This trial is sponsored by NxStage Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00288613 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
International (Pediatric) Peritoneal Biobank
RECRUITING
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RECRUITING
-
Kidney Function in Sickle Cell Anemia
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Kidney Failure, Chronic
All registered trials for this condition
End Stage Renal Disease, Requiring Dialysis
All registered trials for this condition
Arkansas
All trials with a study site in Arkansas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.